Discover key shareholder updates in Indivior PLC's latest Form 6-K, filed on February 25, 2025. Stay informed on ownership changes affecting your investments.
Indivior PLC reports FDA approval for SUBLOCADE label changes, enhancing marketability and compliance. Key insights on regulatory impact and investor confidence.
Explore Indivior PLC's Form 6-K/A amendment detailing financial results, regulatory compliance, and investor insights for February 2025.
Discover Indivior PLC's latest financial report filed as Form 6-K, detailing unaudited financials, compliance with IFRS, and strategic updates for FY 2024 and beyond.
This report details Indivior PLC's Form 6-K regarding the delayed FDA approval of SUBLOCADE label changes, impacting investor sentiment and market outlook.
Explore Indivior PLC's January 14, 2025 Form 6-K report on share repurchases, compliance, and strategic insights.
Indivior PLC's January 2025 Form 6-K discloses historical financials per US GAAP, enhancing transparency for US investors. Compliance with SEC standards is confirmed.
Explore Indivior PLC's January 2025 Form 6-K filing, revealing vital ownership changes and compliance with SEC regulations. Essential reading for investors and analysts.
Discover key insights from Indivior PLC's SEC Form 6-K filed on Jan 7, 2025, detailing a significant transaction in own shares and compliance with SEC regulations.
Explore Indivior PLC's January 2025 Form 6-K report detailing total voting rights, essential for shareholders. Signed by Kathryn Hudson, it's crucial for investor understanding.
Review Indivior PLC's Form 6-K filing, highlighting shareholder activities, ownership changes, and key announcements from December 31, 2024. Essential insights for investors.
Indivior PLC's Form 6-K reveals a recent share buyback transaction, impacting shareholder value. Filed on December 31, 2024, it complies with SEC regulations for foreign issuers.